Ananda Pharma Plc (AQU:ANA)

Market Cap	2.45M -85.1%
Revenue (ttm)	4.43K +480.2%
Net Income	-4.51M
EPS	-0.00
Shares Out	4.45B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	0.0475
Day's Range	n/a
52-Week Range	0.0300 - 0.5350
Beta	0.65
RSI	28.10
Earnings Date	Jan 14, 2026

About Ananda Pharma

Ananda Pharma Plc, along with its subsidiaries, operate as a biopharmaceutical company that develops cannabidiol-based medicine to treat endometriosis and chemotherapy-induced peripheral neuropathy chronic conditions across the United Kingdom and internationally. Its lead product, MRX1, is in Phase 2a feasibility trials for endometriosis-related pain and in a Phase 2 efficacy study to investigate chemotherapy-induced peripheral neuropathy. The company also offers MRX2 and MRX2t, which are cannabinoid-based medicines in Phase 3 clinical trials f...

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 9
• Stock Exchange: Aquis Exchange
• Ticker Symbol: ANA